Janux Therapeutics JANX Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Operating margin | -1,576.7%-643pp | -933.6%-30.7pp | -902.9%-124pp | -779%+126pp | |
| Net margin | -1,136.3%-485pp | -651.6%+69.6pp | -721.2%+11.0pp | -732.2%+166pp | |
| EBITDA margin | -1,556.4%-642pp | -914.1%-35.4pp | -878.7%-109pp | -769.3%+133pp | |
| Free cash flow margin | -832.8%-416pp | -417.2%+231pp | -648.6%-75.3pp | -573.2%-65.7pp | |
| Returns | |||||
| Return on equity | -11.5%-1.4pp | -10.1%+7.4pp | -17.5%+0.8pp | -18.4%— | |
| Return on assets | -11%-1.4pp | -9.6%+6.1pp | -15.7%+1.3pp | -17%-0.5pp | |
| Return on invested capital | -20.5%0.0pp | -20.5%+2.2pp | -22.7%-1.2pp | -21.5%— | |
| Efficiency | |||||
| Asset turnover | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Liquidity | |||||
| Current ratio | 39×-20.2× | 59.2×+32.4× | 26.8×+6.7× | 20.1×-9.3× | |
| Quick ratio | 39×-20.2× | 59.2×+32.4× | 26.8×+6.7× | 20.1×-9.3× | |
| Cash ratio | 2.1×-22.6× | 24.7×+23.2× | 1.5×-1.6× | 3.1×+0.3× | |
| Leverage | |||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0.1×0.0× | 0.1×+0.1× | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0.1×0.0× | 0.1×+0.1× | |
| Per Share | |||||
| Book value per share | $15.44-18.9% | $19.03+143% | $7.82+1.1% | $7.73-50.3% | |
| Valuation | |||||
| Market capitalization | $892.81M-36.3% | $3.14B+527% | $500.92M-8.5% | $547.66M-32.8% | |
| Enterprise value | $862.55M-36.2% | $2.73B+440% | $506.25M-2.9% | $521.54M-33.1% | |
| Price / sales | 65×-85.2× | 296.5×+235× | 62×-1.6× | 63.6×-161× | |
| Price / book | 0.9×-0.4× | 3.1×+1.6× | 1.5×-0.3× | 1.7×-0.5× | |
| EV / sales | 62.5×-81.6× | 258×+195× | 62.6×+2.1× | 60.6×-154× | |
| Free cash flow yield | -8.8%-5.5pp | -1.4%+9.1pp | -10.5%-1.5pp | -9%-6.7pp | |
| Earnings yield | -12.9%-7.3pp | -2.2%+9.4pp | -11.6%-0.1pp | -11.5%-7.5pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Janux Therapeutics's ratios come from?
- Every ratio is computed from Janux Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
